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Abstract
Background: C3 hypocomplementemia and the presence of C3 nephritic factor (C3NeF), an autoantibody causing
complement system over-activation, are common features among most patients affected by Barraquer-Simons
syndrome (BSS), an acquired form of partial lipodystrophy. Moreover, BSS is frequently associated with autoimmune
diseases. However, the relationship between complement system dysregulation and BSS remains to be fully
elucidated. The aim of this study was to provide a comprehensive immunological analysis of the complement
system status, autoantibody signatures and HLA profile in BSS. Thirteen subjects with BSS were recruited for the
study. The circulating levels of complement components, C3, C4, Factor B (FB) and Properdin (P), as well as an
extended autoantibody profile including autoantibodies targeting complement components and regulators were
assessed in serum. Additionally, HLA genotyping was carried out using DNA extracted from peripheral blood
mononuclear cells.
Results: C3, C4 and FB levels were significantly reduced in patients with BSS as compared with healthy subjects.
C3NeF was the most frequently found autoantibody (69.2% of cases), followed by anti-C3 (38.5%), and anti-P and anti-
FB (30.8% each). Clinical data showed high prevalence of autoimmune diseases (38.5%), the majority of patients (61.5%)
being positive for at least one of the autoantibodies tested. The HLA allele DRB1*11 was present in 54% of BSS
patients, and the majority of them (31%) were positive for *11:03 (vs 1.3% allelic frequency in the general population).
Conclusions: Our results confirmed the association between BSS, autoimmunity and C3 hypocomplementemia.
Moreover, the finding of autoantibodies targeting complement system proteins points to complement dysregulation
as a central pathological event in the development of BSS.
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Background
Lipodystrophies are a heterogeneous group of rare
diseases characterized by loss of adipose tissue. They can
be divided into generalized, partial or localized depend-
ing on the extent of fat loss. Additionally, both,
generalized and partial forms can be classified as inher-
ited and acquired [1]. Barraquer-Simons syndrome (BSS)
(ORPHA: 79087), is an acquired form of partial lipody-
strophy, characterized by bilateral symmetrical loss of
adipose tissue that begins in the face and may variably
spreads to neck, shoulders, arms and trunk, keeping
intact the adipose tissue of the lower extremities [2].
Sometimes, after puberty, mainly in women, adipose
tissue is hypertrophic in the lower extremities, causing a
regional disproportion. Females are more affected than
males with a ratio of 4:1 [3, 4]. There is usually no family
history of lipodystrophy. Onset of the disease usually
occurs during childhood or adolescence, sometimes after
viral infections [5]. As opposed to other types of
lipodystrophies, metabolic diseases and associated
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comorbidities appear less common in patients with BSS
[4, 5], though some of them can present severe meta-
bolic complications [6]. Several reports have shown the
association of BSS with autoimmune diseases in a mi-
nority of patients, in particular systemic lupus erythema-
tosus and dermatomyositis. Other autoimmune diseases
that are less frequently associated with BSS include auto-
immune thyroiditis, localized scleroderma, idiopathic
thrombocytopenic purpura and Sjögren’s syndrome,
among others [4, 5, 7].
A common feature among patients with BSS is the C3
hypocomplementemia [5]. Sissons et al. [8] provided a
comprehensive study of the association of BSS with com-
plement dysregulation. In that study, most patients with
C3 consumption had detectable levels of an IgG/IgM
autoantibody called C3 nephritic factor (C3NeF). C3NeF
stabilizes the enzymatic complex C3 convertase (C3bBb),
which causes unopposed activation of the alternative path-
way (AP) of the complement system [9]. The presence of
this autoantibody has been associated with a rare entity
named C3 glomerulopathy (C3G) [10]. C3G is a kidney
disease characterized by C3 predominant staining and
minimal or absent immunoglobulin staining observed on
renal biopsy by immunofluorescence [11]. The incidence
of C3G is approximately 1 per million per year [12]. C3G
is divided into dense deposit disease (DDD) and C3 glom-
erulonephritis (C3GN), based on electron microscopy
findings [13]. The most important adverse outcome
associated with the diagnosis of C3G is progression to
end-stage renal disease, which occurs within 10 years from
diagnosis in ~ 70% of affected children and 30–50% of
affected adults [13]. Concerning patients with BSS, 20% of
the them eventually develops C3G [2, 4].
Adipocytes are the main source of synthesis and secre-
tion of a serine protease called adipsin or factor D (FD)
[14–16]. This enzyme is considered the key limiting fac-
tor for the activation of the AP. FD cleaves factor B (FB)
when it forms part of the C3 pro-convertase (C3bB),
generating the active AP C3 convertase. Moreover,
adipocytes also express other components of the AP,
such as C3, FB and complement regulators like proper-
din (P), factor H (FH) and factor I (FI) [17–20]. Further-
more, local complement activation appears to be
involved in the synthesis of triglycerides and adipocyte
differentiation [17]. Although the connection between
complement abnormalities and renal disease has been
established, the exact mechanism of fat loss remains un-
clear. Mathieson and collaborators demonstrated that
C3NeF could induce complement-mediated lysis of adi-
pocytes in vitro [21]. However, the fact that only a small
proportion of patients with C3NeF develop lipodystro-
phy remains unexplained.
We herein describe the immunological and clinical
characteristics of a group of 13 patients diagnosed with
BSS. Our results show that C3 hypocomplementemia
and C3NeF autoantibodies are present in approximately
70% of the patients; besides, we found the presence of
other autoantibodies against individual complement
components. Immunological studies were extended with
Human Leukocyte antigen (HLA) phenotyping and the
screening of autoimmune markers.
Results
Demographic and clinical data
Demographic details and basic clinical information are
listed in Table 1. In our cohort, patients were mainly
female (ratio 5.5:1) and the mean age at the time of the
study was 33 (range 8–76). Lipodystrophy onset oc-
curred during childhood (mean 8 years) in most cases
and only one patient, BSS6, developed the disease in
adulthood (41 years old) after the implantation of ortho-
dontic brackets. Most of the patients conserved the body
mass index (BMI) into normal range, and some them
registered slight decreases of the percentage of whole
total fat mass. Regarding glucidic metabolism, one
patient had elevated insulin and HbA1c levels and was
diagnosed with diabetes. Mild low leptin levels (8.03 ng/
ml; normal range: 15.3 ± 8.1 standard deviation) were
present in one patient and triglycerides, total cholesterol
and LDL-cholesterol levels were elevated in two patients.
Three patients were diagnosed with fatty liver, linked to
higher concentrations of AST and ALT transaminases.
BSS1 suffered a hepatitis B virus (HBV) infection that
lead to the deterioration of liver function with elevation
of transaminases and development of hepatocellular
carcinoma which shortly ended in death. Concerning
cardiovascular diseases, three patients developed arterial
hypertension. Finally, BSS1, BSS3 and BSS9 were diag-
nosed with DDD, IgA nephropathy and C3GN,
respectively.
Complement system profile in patients with BSS
C3 levels were significantly reduced (P = 0.01) in the group
of patients with BSS [median 31.7mg/dl (IQR, 10.4–
100.8)] in comparison with healthy donors (NHS) [100.5
mg/dl (85.2–111.5)] (Fig. 1a). The same applies for C4
[BSS, 16.5mg/dl (14.1–23.5); NHS, 25mg/dl (19.3–27.7);
P = 0.04] and FB levels [BSS, 16.5mg/dl (14.1–23.5); NHS,
25mg/dl (19.3–27.7); P = 0.04] (Fig. 1b), that presented
significant differences between both groups.
Conversely, similar P levels were found in controls and
BSS patients [BSS, 26.7 mg/dl (23.9–29.7) versus NHS,
28.7 mg/dl (24.9–32.3), P = 0.22] (Fig. 1d).
C3NeF is not the only autoantibody against AP
components in patients with BSS
The frequencies of these autoantibodies are shown in
Table 2. C3NeF was the most frequent autoantibody
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(69.2% of cases) observed in sera from patients with BSS,
in accordance with previous observations [2, 4, 5].
Additional autoantibodies against the AP C3 convertase
(C3bBbP) components were also detected. Autoanti-
bodies against P were the most prevalent (38.5% of
cases), followed by anti-C3 and anti-FB autoantibodies
(30.8% for both). Moreover, the presence of one or more
of these autoantibodies was always associated with C3
consumption. However, none of them showed significant
reactivity against complement negative regulators FH
and FI. Autoantibodies against complement proteins
were not found in the 20 healthy subjects analyzed as
control population. A schematic representation of these
autoantibodies and their antigens is shown in
Additional file 1: Figure S1.
Profile of HLA alleles in patients with BSS
To investigate the immunogenetic variables potentially
associated with BSS we determined the HLA class I and
class II phenotypes (Table 3). The very low sample size
and the enormous polymorphism of the HLA system
preclude a proper, statistically powered, study of associ-
ation. However, examination of phenotypes reveals that:
(i) no HLA allele was shared by all, or a vast majority of
BSS patients; (ii) notwithstanding, 3/9 Spanish and 1/4
Italian patients (ca. 31%) carried allele DRB1*11:03, re-
ported in Spaniards at an allelic frequency of ~ 1.3%
(calculated carrier frequency ~ 2.6% [22]), the global fre-
quency of all DRB1*11 alleles in BSS patients being 54%;
and (iii), no patient carried B*07, B*14 and DRB1*15
alleles, all common in European Caucasoids. Future
studies in larger patients’ cohorts should address
whether these observations reflect a real predisposing
effect.
Autoimmunity and autoimmune diseases are prevalent in
patients with BSS
The profile of autoantibodies and related diseases are
summarized in Table 4. Clinical data from the 13 pa-
tients showed a high prevalence of autoimmune diseases
(38.5%) including Hashimoto’s thyroiditis (n = 2), vitiligo
(n = 1), Sjögren’s syndrome (n = 1) and rheumatoid
Table 1 Clinical and demographical data of patients with BSS
Variable BSS1 BSS2 BSS3 BSS4 BSS5 BSS6 BSS7 BSS8 BSS9 BSS10 BSS11 BSS12 BSS13 Reference
Sex F F F F F F F F M M F F F
Age (years) 76 13 15 8 49 42 41 44 52 11 62 10 12
Lipodystrophy onset
(years)
N/A 2 5 4 9 41 7 3 6 7 8 7 7
BMI (kg/m2) 24.3 19.3 18 16.3 19.8 22.3 33.8 22.7 23.5 21.3 26.1 16.5 22.7 18–25




Acanthosis No No No No No No No No No No No No No Yes/No
Glucose (mg/dL) 79 85 69 86 83 93 82 102 84 90 107 94 84 60–110
Insulin (μU/mL) 15.8 10.4 10.7 13.5 N/A N/A 18.5 9.8 13 14.3 33.3 9 4.74 2.6–24.9
Diabetes No No No No No No No No No No Yes No No Yes/No
HbA1c (%) N/A 4.8 N/A 5.3 5.2 N/A 5.4 N/A N/A 5.2 6.4 5.1 5.2 4.0–5.5
Hypoleptinemia No No Yes No No No No No No No No No No Yes/No
Triglycerides (mg/dL) 106 79 110 89 78 66 105 210 445 61 265 79 53 25–115
Total colesterol (mg/dL) 129 145 122 163 238 183 158 120 245 112 175 167 159 110–230
HDL-cholesterol (mg/dL) 57 62 N/A 42 69 70 63 35 45 45 37 44 66 40–70
LDL-cholesterol (mg/dL) 120 109 N/A 112 153.4 100 74 111 163 64 110 126 101 50–129
Fatty liverb No No No No No No Yes No No Yes Yes No No Yes/No
ALT (UI/L) 33 28 13 24 31 20 60 21 21 15 24 22 28 5–31
AST (UI/L) 51 24 23 33 26 19 39 15 15 24 25 25 20 5–32
Hypertension Yes No No No No No No No Yes No Yes No No Yes/No
Renal disease Yes (DDD) No Yes (IgAN) No No No No No Yes (C3GN) No No No No Yes/No
Abbreviations: F female, M male, BMI Body Mass Index, HbA1c Glycohemoglobin, ALT Alanine aminotransferase, AST Aspartate aminotransferase; DDD Dense
deposit disease, IgAN IgA nephropathy, C3GN C3 glomerulonephritis, N/A Not available
a Percentage of total fat was measured using dual-energy x-ray absorptiometry
b Liver steatosis was assessed by means of ultrasonography
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Fig. 1 Complement profile in Barraquer-Simons syndrome (BSS) cohort. (a) C3 levels, (b) C4 levels (c) Factor B (FB) levels and (d) properdin (P)
levels. Data are represented by median with interquartile ranges. The results of the BSS cohort (n = 13) are compared with a group of 20 healthy
subjects (NHS). Data is statistically significant for P < 0.05
Table 2 Frequencies of autoantibodies against complement proteins in patients affected by BSS
C3NeF anti-C3 anti-FB anti-P anti-FI anti-FH C3 (mg/dl)
BSS1 Positive Positive Negative Negative Negative Negative 3.0
BSS2 Positive Positive Negative Negative Negative Negative 11.9
BSS3 Positive Positive Positive Positive Negative Negative 31.7
BSS4 Positive Positive Negative Negative Negative Negative 7.9
BSS5 Positive Negative Negative Negative Negative Negative 14.8
BSS6 Negative Negative Negative Negative Negative Negative 88.5
BSS7 Positive Negative Positive Positive Negative Negative 38.7
BSS8 Negative Negative Negative Negative Negative Negative 121.0
BSS9 Positive Negative Positive Positive Negative Negative 20.6
BSS10 Positive Negative Positive Positive Negative Negative 50.2
BSS11 Negative Negative Negative Negative Negative Negative 127.0
BSS12 Positive Negative Negative Positive Negative Negative 8.9
BSS13 Negative Negative Negative Negative Negative Negative 113.0
9/13 (69.2%) 4/13 (30.8%) 4/13 (30.8%) 5/13 (38.5%) 0/13 (0%) 0/13 (0%) Range: 75–135mg/dl
Abbreviations: C3NeF C3 nephritic factor, FB factor B, P properdin, FI factor I, FH factor H
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arthritis (n = 1). Moreover, 61.5% of patients were posi-
tive for one or more autoantibodies tested and ANA
were detected in 30.8% at a 1/160 titer in all cases.
Two patients (BSS5 and BSS7) who were diagnosed
with Hashimoto’s thyroiditis were positive for anti- TG-
Ab and one of them (BSS7) for TPO-Ab. Patients BSS10
and BSS12 were positive for DAT or Coombs test but
they were not affected with autoimmune hemolytic
anemia at the time the study was performed. Another
patient with Hashimoto’s thyroiditis also presented with
vitiligo and Sjögren’s syndrome (BSS7). One patient had
active rheumatoid arthritis with elevated rheumatoid
factor (BSS1). APCA and Glutamic Acid Decarboxylase
GAD-Ab were found in one patient (BSS13) but no re-
lated diseases have been developed at present. No
dermatomyositis-related autoantibodies were detected in
any patient.
Discussion
Abnormalities in the AP of the complement system are
highly frequent in patients with BSS [2, 3, 5, 8]. Presum-
ably as a consequence of AP dysregulation, C3 hypo-
complementemia has been reported in 70–80% of
patients with BSS [3]. Moreover, this feature is widely
established as a critical marker for the differential diag-
nosis of this type of lipodystrophy [4].
In the present study and in line with previous reports,
C3 hypocomplementemia was found in 69.3% of the
patients all of whom were positive for C3NeF (Fig. 1a)
[5, 8]. Furthermore, BSS patients in our series also had
significantly low FB levels as compared to controls (Fig.
1c). FB is a complement protein subjected to proteolytic
cleavage by FD during the activation of the AP. FB levels
may indeed be reduced in patients with C3NeF but this
is not a constant finding. This issue has been debated in
several works but there are heterogeneous results con-
cerning FB levels in the published series [23–25]. During
AP activation, in the absence of C3NeF, C3 and FB con-
sumption are usually correlated; however, C3NeF breaks
this correlation. One molecule of FB is needed for the
Table 3 HLA profiles of patients affected by BSS
Patient
BSS1 A*01:01,*30:02 B*08:01,*18:01 C*05:01,*07:01 DRB1*03:01 DQB1*02:01 DQA1*05:01 DPB1*01:01,*02:02
BSS2 A*02:01,*11:01 B*35:01,*57:03/
B*35:04,*57:01
C*04:01,*07:01 DRB1*11:03,*14:54 DQB1*03:01,*05:03 DQA1*01:04,*05:05/09 DPB1*04:01
BSS3 A*03:01,*11:01 B*27:05,*35:01 C*01:02,*04:01 DRB1*01:01,*04:03 DQB1*03:02,*05:01 DQA1*01:01,*03:01 DPB1*04:01
BSS4 A*02:01,*24:02 B*40:06,*49:01 C*07:01,*15:02 DRB1*01:01,*11:03 DQB1*03:01,*05:01 DQA1*01:01,*05:05/09 DPB1*02:01,*04:01
BSS5 A*03:01,*29:02 B*18:01,*44:02 C*05:01 DRB1*03:01,*11:01 DQB1*02:01,*03:01 DQA1*05:01,*05:05/09 DPB1*04:01
BSS6 A*11:01,*24:02 B*53:01,*57:01 C*04:01,*06:02 DRB1*07:01,*13:02 DQB1*03:03,*06:04 DQA1*01:02,*02:01 DPB1*03:01,*04:02
BSS7 A*29:02,*68:01 B*44:02,*49:01 C*07:01,*07:04 DRB1*04:01,*07:01 DQB1*02:02,*03:01 DQA1*02:01,*03:01 DPB1*04:01
BSS8 A*02:01,*24:02 B*15:01,*41:02 C*03:03,*17:01/
17:03
DRB1*11:03,*13:03 DQB1*03:01 DQA1*05:05/09 DPB1*04:01,*04:02
BSS9 A*32:01,*68:01 B*35:08,*51:01 C*04:01,*15:02 DRB1*04:03,*13:01 DQB1*03:02,*06:03 DQA1*01:03,*03:01 DPB1*02:01,*04:01
BSS10 A*02:01,*24:02 B*15:01,*18:01 C*03:03,*12:03 DRB1*04:01,*11:04 DQB1*03:01,*03:02 DQA1*03:01,*05:05/09 n.s.
BSS11 A*02:01,*24:02 B*35:01,*45:01 C*04:01,*07:02 DRB1*11:01,*11:03 DQB1*03:01 DQA1*05:05/09 n.s.
BSS12 A*02:01 B*27:05,*39:06 C*02:02,*07:02 DRB1*08:01,*13:01 DQB1*04:02,*06:03 DQA1*01:03,*04:01 n.s.
BSS13 A*02:01,*11:01 B*44:02,*55:01 C*03:03,*05:01 DRB1*10:01,*16:01 DQB1*05:01,*05:02 DQA1*01:01/04/05,*01:02 n.s.
The most likely HLA alleles at four-digit resolution, assigned as indicated in Materials and Methods, are displayed for each patient. Slashes represent ambiguities in
the phenotype; n.s. not studied
Table 4 Clinical and laboratory markers of autoimmunity in
patients affected by BSS
Autoimmune markers Autoimmune disease




BSS5 TG-Ab Hashimoto’s thyroiditis
BSS6 – –
BSS7 TG-Ab, TPO-Ab Hashimoto’s thyroiditis,
vitiligo, Sjögren’s syndrome
BSS8 – –
BSS9 ANA (1:160) –
BSS10 DAT+ –
BSS11 ANA (1:160) –
BSS12 DAT+, ENA (Anti Ro52Ab),
ANA (1:160)
–
BSS13 APCA, ANA (1:160), GAD-Ab –
Abbreviations: Anti-dsDNA anti-double stranded DNA, RF rheumatoid factor,
TG-Ab thyroglobulin antibody, TPO-Ab thyroid peroxidase antibody, ANA anti-
nuclear antibody, DAT Direct Antiglobulin Test, APCA anti-parietal cell
antibody, GAD-Ab Glutamic Acid Decarboxylase autoantibodies; −, absent
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assembly of one AP C3 convertase. C3NeF stabilizes the
C3 convertase so that thousands of C3 molecules are
proteolyzed by this complex leading to C3 consumption
with no need for further convertase formation and
subsequent FB consumption. This stabilizing effect of
C3NeF is heterogeneous among individuals, so it may be
hypothesized that the decrease of FB levels is correlated
with the stabilizing ability of the heterogeneous C3NeF
pool in each patient. Strikingly, P levels remained nor-
mal in our cohort (Fig. 1d). One possible explanation is
that P is not the target of proteolytic cleavages and its
consumption during the activation of the AP is unlikely.
Activation of the classic pathway (CP), resulting in low
C4, has been described in some patients with acquired
generalized lipodystrophy (AGL), though not being con-
sidered an specific feature of this pathology [26, 27]. In
our study, C4 levels were significantly lower in BSS pa-
tients compared to controls (Fig. 1b). This observation
suggests that, in BSS, as previously described, the activa-
tion of both CP and AP may occur [8]. The activation of
CP could be explained as a consequence of the forma-
tion of antigen-antibody complexes. Interestingly, in
patients who tested positive for the presence of anti-
bodies against C3 (BSS1 to BSS4, see Table 2), one of
the most abundant plasmatic proteins, lower C4 levels
were found, probably as a consequence of the higher ti-
ters of circulating immune-complexes. However, further
studies are needed to confirm this association.
In this report, age- and sex-matched healthy subjects
were not available as controls, which is a limitation of
the study. Other authors have previously shown that
complement protein levels modify during aging; how-
ever, C3, C4, FB or P (proteins quantified in this work)
do not exhibit significant variation with aging [28] and
linear regression studies performed on our data have
confirmed that aging is not influencing the results of the
study (Additional file 1: Figure S2). Moreover, previous
reports have established the normal variation range of
C3 and C4 complement levels with age [29], and data
presented here for patients with BSS are out of normal
ranges, again indicating that the observed variation is
not due to aging.
Females were overrepresented in both our patient and
control cohorts (85 and 60%, respectively). According to
Gaya da Costa et al. [28], the levels of C3 and P are also
significantly lower in women in comparison with men,
which would result in significant bias in quantitative
studies. To discard such effect, we compared the levels
of C3, C4, FB, and P between sexes, and no significant
differences for any complement component were found
in our cohort of healthy subjects (Additional file 1:
Figure S3).
Our results demonstrate an association between the
presence of autoantibodies directed against proteins of
the AP and altered complement levels in patients with
BSS. All of those patients with BSS and severe C3 con-
sumption were positive for at least one of the analyzed
autoantibodies the more prevalent being C3NeF (Table
2). C3NeF is associated with a predisposition to develop
kidney disease in the medium to long term, which may
explain why some patients in our series have developed
C3G (BSS1 and BSS9) and IgA nephropathy (BSS3)
(Table 1). C3G and IgAN are two diseases with different
pathophysiological bases that share marked dysregula-
tion of the complement system. Although associations
between IgAN and glomerular and circulating markers
of complement activation are established, the mechan-
ism of complement activation and contribution to
glomerular inflammation and injury is not defined. All
reports had described that C3G is the main cause of
renal disease in patients with BSS and in these cases ac-
tivation of the AP is the main mechanism involved in
complement dysregulation. In the IgAN, lectin and AP
could be involved in the activation of the complement
system. This case with IgAN and BSS could be the result
of an association of two entities in which complement
consumption should be mostly related with the presence
of an IgG with C3NeF activity. However, we cannot rule
out this to be an accidental finding not related to the
lipodystrophic phenotype.
Regarding the antibodies against additional comple-
ment proteins (C3, FB and P) it should be noted that
they were detected only in patients who were also posi-
tive for C3NeF (Table 2). Accordingly, it is reasonable to
speculate that whatever the mechanism leading to the
break of immunological tolerance, if the C3bBb conver-
tase (with or without P) bears the neoepitope targeted
by C3NeF, additional autoantibodies directed against
single proteins of this complex could be concurrently
generated. Of note, autoantibodies against negative
regulators of the AP (FH and FI) were not found in these
patients (Table 2). Unlike C3NeF, whose importance in
lipodystrophy has been largely studied and validated,
autoantibodies against individual components of the
C3 convertase have never been previously described
in BSS. Anti-FB autoantibodies were first reported in
a patient with DDD by Strobel and coleagues [30].
Their study revealed that they prevented the spontan-
eous dissociation of the C3 convertase of the AP and
increased its normal half-life, thus causing systemic
complement activation in the patient [30]. Additional
patients with anti-FB and anti-C3b autoantibodies
have since been reported in C3G and Ig-Associated
Membranoproliferative Glomerulonephritis cohorts
supporting their pathological role in the dysregulation
of the AP [31, 32]. Therefore, further studies are
needed in order to clarify if anti-FB and anti-C3b
autoantibodies have a primary mechanistic role in the
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pathology of the lipodystrophy or if they rather sec-
ondarily arise as a consequence of the increase in cir-
culating complement proteins produced due to
unabated complement activation in the presence of
C3NeF. A plausible possibility in line with the pres-
ence of C3NeF and low C3 levels in our BSS cohort
is that these autoantibodies synergistically promote
further C3 convertase stabilization and C3 consump-
tion in serum, similarly to what has already been de-
scribed by Vasilev and colleagues for anti-C3 and
anti-C3b autoantibodies in patients with lupus neph-
ritis [33, 34].
Although the etiology of BSS is generally unknown,
several studies have described its association with signs
of autoimmunity [5, 7, 35], a feature which is considered
a supportive clinical criterion for the diagnosis to BSS
[5]. Patients have been recruited in Italy and Spain, and
autoantibody screening has been performed in both
countries. To minimize the bias due to different meth-
odology and interpretation, especially in the case of in-
direct immunofluorescence studies, autoantibody
analysis was centralized in one laboratory from each
country (La Paz University Hospital and University Hos-
pital of Pisa). These determinations were performed in
clinical routine laboratories with broad experience in
autoimmunity and using validated methods. This study
demonstrates a strong association of BSS with auto-
immunity because 61.5% of the patients are positive for
one or more autoantibodies, and 38.5% of them devel-
oped autoimmune-related disorders (Table 4). The pa-
tient BSS1 suffered from chronic HBV infection that
could be associated with the presence of rheumatoid
arthritis and markers of autoimmunity (RF and anti-
dsDNA Ab). Several reports have illustrated the mecha-
nisms involved in the loss of tolerance as a consequence
of the immune response to HBV infection: such as
molecular mimicry between HBV antigens and self-
proteins, generation of immune complexes between
HBV antigens and antibodies, promotion of apoptosis/
tissue damage. All the above mentioned mechanisms
culminate in the exposure of intracellular antigens to the
immune system and may end up with the development
of a variety of autoimmune diseases [36, 37].
Since the first description of anti-adipocyte autoanti-
bodies in a patient with AGL by Hübler and colleagues
[38], its existence in BSS has been discussed. The results
of the present study provide additional supportive evi-
dence for a different autoimmune etiological basis for
BSS according to which either local or systemic comple-
ment activation induced by autoantibodies against the
C3 convertase of the AP or its individual components
may play a relevant role.
We hypothesized that genetic and/or environmental
factors a role in the disease onset. Among the
putative genetic factors, HLA region on chromosome
6 is a reasonable candidate, as demonstrated through
strong associations with a large variety of auto-
immune or inflammatory diseases [39] such as type 1
diabetes and celiac disease [40, 41], Juvenile Auto-
immune thyroiditis or ankylosing spondylitis with
HLA-B*27 association [42, 43]. Although no HLA al-
lele was shared by the majority of our patients, inter-
estingly, the allele DRB1*11:03 were overrepresented
in our cohort (31% carrier frequency vs 1.3% allelic
frequency in the general population) [22]) (Table 3).
There are hundreds of polymorphisms of HLA-DRB1
which have been associated with different auto-
immune disorders as well as with immune response
to infection and vaccines The association between
HLA-DRB1*11 and autoimmune, infectious and can-
cer diseases has been previously reported for: systemic
sclerosis, Henoch-Schönlein purpura, systemic juvenile
idiopathic arthritis, Helicobacter pylori-positive idio-
pathic thrombocytopenic purpura, hairy cell leukae-
mia, cervical cancer, among others [44–49]. There are
at least two reports dealing with an apparent associ-
ation of the allele DRB1*11:03 with forms of juvenile
idiopathic arthritis [50, 51]. Future studies in larger
patients’ cohorts should address whether this allele is
a real biomarker of BSS or not.
Conclusions
We here confirm that C3, and to a lower extent, C4
hypocomplementemia are common features of BSS, and
that this pathology is frequently associated with
autoimmunity. Moreover, besides C3NeF, other auto-
antibodies directed against components of the C3 con-
vertase of the AP (anti-C3, anti-FB and anti-P) are
present in a significant proportion of patients from our
cohort. Finally, an association with the HLA allele
DRB1*11:03 was observed, suggesting a potential role of
this variant as a marker of the disease.
Methods
Patients
Thirteen patients were diagnosed with BSS on the basis
of fat loss during childhood or adulthood affecting upper
areas of the body, and having ruled out other causes of
fat loss. The diagnosis was made based on standardized
criteria [1]. The presence of other autoimmune diseases
can be of support of the diagnosis. Laboratory findings
as low serum C3 and the presence of C3NeF were used
during the diagnosis. Familial Partial Lipodystrophy
(FPL) was also excluded based on the natural course of
the disease, clinical features, age at onset, and absence of
pathogenic variants in FPL-related genes (LMNA,
PPARG, PLIN1, CIDEC, LIPE, ADRA2A, AKT2). No con-
sanguinity was reported in any case.
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Biological samples
We collected serum samples from 13 patients with BSS (9
from Spain, and 4 from Italy) and 20 healthy subjects
(NHS) (60% female, aged 25–61 years). Controls and pa-
tients are not matched for age. Serum and EDTA plasma
samples were obtained under standard conditions upon
informed consent from the donors; blood was collected in
plain tubes, allowed to clot at room temperature, and cen-
trifuged for 10min at 4 °C. Serum and plasma were then
aliquoted and stored frozen at − 80 °C until their use.
Measurement of the levels of complement system
proteins
Serum C3 and C4 levels were measured by nephelome-
try (Siemens Healthcare, Erlangen, Germany). FB and P
levels were measured using in-house ELISA assays, pre-
viously described by our group [23].
C3NeF detection by enzyme-linked immunosorbent assay
(ELISA)
C3NeF detection in serum samples was performed as
described previously by Paixão- Cavalcante and
collaborators [24] with several modifications. Briefly, re-
sidual Bb was detected using a monoclonal anti-Bb anti-
body (A227, Quidel) (1:500; 1 h, 37 °C), followed by
peroxidase-conjugated goat anti-mouse IgG (Jackson
Immunoresearch, West Grove, PA, USA) (1:5000; 1 h).
Color was developed using o-phenylenediamine dihy-
drochloride (Sigma-Aldrich, Madrid, Spain) and absorb-
ance was measured at 492 nm. Samples were considered
positive when optical density was higher than 0.3 units
of absorbance.
Detection of autoantibodies against alternative pathway
components (C3, FB and P) and regulators (FI and FH) by
ELISA
ELISA plates were coated with 100 ng/well of purified
C3, FB, FI, FH, or P. Plates were blocked with PBS-BSA
3% in case of FB and P, and with PBS-BSA 0.1% in FI
and C3. Serum samples were diluted in PBS-BSA 0.1%,
and binding of autoantibodies was detected with
polyclonal anti-human IgG-HRP conjugated antibody
(Jackson Immunoresearch) in ABTS substrate, as de-
scribed by Nozal et al. [52]. Factor H autoantibodies
were searched following methods previously described
by Abarrategui-Garrido et al. [53]
HLA genotyping
HLA typing has been performed by two different labora-
tories. The methodology developed by each laboratory is
described below:
- Spain: HLA-A, −B, −C, −DRB1, −DQB1 and -DQA1
were studied by polymerase-chain reaction with
sequence-specific oligonucleotide probes (PCR-SSOP)
using commercial reagents (details available upon re-
quest). Those reagents distinguish all two-digit allelic
groups and also discriminate most four-digit alleles com-
monly seen in the Spanish population [22, 40, 54–56]. In
addition, we determined DPB1 phenotypes and con-
firmed DRB1*11:03 by sequence-based typing using local
reagents. All HLA typing studies were performed
following the quality standards issued by the European
Federation for Immunogenetics.
- Italy: A single PCR reaction was used for each HLA
locus. Luminex-based technology was applied to dis-
criminate among the different human HLA alleles, by
using sequence-specific oligonucleotide probes bound to
color-coded microbeads in order to identify HLA alleles
encoded by the DNA sample [57]. A flow analyzer
identifies the fluorescent intensity SAPE on each micro-
sphere. A software was used to assign positive or nega-
tive reactions based on the strength of the fluorescent
signal.
Screening of autoantibodies
The screening of autoantibodies was performed by two
different laboratories. The methodology developed by
each laboratory is described below:
- Spain: Anti-cellular autoantibodies were tested by
indirect immunofluorescence (IIF) on Hep-2 cells
(Euroimmun, Luebeck, Germany), and ENA analysis was
performed, either of IIF was positive or not, by Bioplex
ANA Screen kit (Bio-Rad, Hercules, CA), which includes
dsDNA, chromatin, centromere B, Scl70, RNP-68 kDa,
RNP-A, Ro/SSA 52 kDa, Ro/SSA 60 kDA, La/SSB, Sm,
Sm/RNP, Jo-1, and P ribosomal proteins as antigens.
Rheumatoid factor (RF) was determined by nephelome-
try (Siemens Healthcare, Erlangen, Germany).
Anti-thyroid peroxidase (TPO-Ab) and anti-
thyroglobulin autoantibodies (TG-Ab) were quantified
by fluorescence enzyme immunoassay (EliA, Phadia-
Thermo Fisher, Freiburg, Germany). Anti-islet cells anti-
bodies and anti-suprarrenal cortex autoantibodies detec-
tion was performed by IIF on monkey pancreas and
monkey suprarenal gland tissues (Immco Diagnostics,
Buffalo, NY and Biosystems, Barcelona, Spain, respect-
ively). Anti-parietal cells autoantibodies (APCA), anti-
mitochondrial and anti-smooth muscle autoantibodies
were tested by IIF on rat liver, kidney and stomach sub-
strates (Euroimmun, Luebeck, Germany).
- Italy: TPO-Ab and TG-Ab (AIA, Tosoh Bioscience
Griesheim, Germany) and Anti-transglutaminase auto-
antibodies (Thermo Fisher Scientific, Waltham, USA)
were detected by fluorescence enzyme immunoassay.
Glutamic Acid Decarboxylase Autoantibodies (GAD-Ab)
were tested by radioimmunoassay (Ria Medipan, Berlin
Germany). APCA (Elisa Orgentc Diagnostika, Mainz,
Germany), and 21-Hydroxylase (21-OH) Autoantibodies
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(Elisa RSR Cardiff, U.K) were quantified using commer-
cial ELISA kits. ANA and dsDNA were tested by IIF
(Euroimmun, Luebeck, Germany). Finally, Direct Anti-
globulin Test (DAT) was analyzed by Column Agglutin-
ation (Ortho Clinical Diagnostics Pencoed, UK).
Statistical analysis
Statistical calculations were performed with Prism version
6.01 (GraphPad Software, La Jolla, CA, USA). Man-Whitney
was used for comparisons among the groups. A P-value of
< 0.05 was considered statistically significant in all analyses.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13023-019-1292-1.
Additional file 1: Figure S1. The alternative pathway of the
complement system and autoantibodies against its proteins. In the
alternative pathway (AP), continuous, low-level activation of C3 by spon-
taneous hydrolysis of the internal C3 thioester, or C3 cleavage by plasma
proteases, generates C3(H2O) or C3b. Activation by the AP leads to the
generation of C3 convertase complexes (C3bBb) that cleave C3 into C3a
and C3b. Additionally, the AP C3 convertase can bind properdin (P), a
positive regulator that stabilizes the enzyme, extending its half-life more
than 10-fold. The activation of the AP is controlled by two different sol-
uble regulatory proteins, as factor H (FH) and factor I (FI). C3 nephritic fac-
tor (C3NeF) is one of the most known autoantibodies which recognized
a neo-epitope in the C3 convertase. Other autoantibodies against com-
plement components (C3, FB or P) and regulators (FH or FI), some of
them with functional activities, have been shown in the figure. Figure
S2. Lack of correlation between complement levels and age. In 20
healthy subjects no correlations were found among age and the levels of
(A) C3, (B) C4 (C) factor B (FB) and (D) properdin (P). These data were ob-
tained using the Spearman Rank correlation coefficient. P < 0.05 were
considered statistically significant. Figure S3. Gender does not signifi-
cantly modify complement levels in our cohort of healthy subjects. In 20
healthy subjects complement levels of (A) C3, (B) C4, (C) factor B (FB),
and (D) properdin (P) were measured. The mean of concentration in
males and females was analyzed by the Mann Whitney test. P < 0.05 was
considered statistically significant.
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